DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemotherapy

NCT07472517 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

670

Enrollment

INDUSTRY

Sponsor class

Conditions

Small Cell Lung Cancer (SCLC)
Extensive-stage Small Cell Lung Cancer (ES-SCLC)

Interventions

DRUG: obrixtamig
DRUG: atezolizumab
DRUG: carboplatin
DRUG: etoposide

Sponsor

Boehringer Ingelheim